Unlike HTS, which screens hundreds of thousands of molecules, FBDD relies on smaller libraries, typically comprising 1,000 to 5,000 low-molecular-mass fragments. This enables more efficient screening, reduced operational costs, and greater practicality in library management. Over the past two decades, FBDD has achieved remarkable milestones, including the approval of drugs (for example: venetoclax, vemurafenib , sotorasib , and pexidartinib ) and the development of over 40 compounds in clinical stages originating from FBDD screenings. This success underscores its significance in addressing various diseases. For computer-guided FBDD, fragments can be obtained through deconstruction methods such as REtrosynthetic Combinatorial Analysis Procedure (RECAP), Breaking of Retrosynthetically Interesting Chemical Substructures (BRICS), and MOlecule fRagmenTAtion fRamework (MORTAR), a framework integrated with three algorithms: ErtlFunctional GroupsFinder, Sugar Removal Utility, and Scaffold Generator. The main advantage of RECAP over MORTAR is identifying molecular features that capture the true diversity of substructures in only a molecular fragment. Another method of obtaining molecular fragments for computer-and experimental-guided FBDD is from commercial vendors or academic groups.